Involvement of Up-Regulation of DR5 Expression and Down-Regulation of c-FLIP in Niclosamide-Mediated TRAIL Sensitization in Human Renal Carcinoma Caki Cells.

Molecules 2018 Sep 5;23(9). Epub 2018 Sep 5.

Department of Immunology, School of Medicine, Keimyung University, 1095 Dalgubeoldaero, Dalseo-Gu, Daegu 42601, Korea.

Niclosamide is used to treat intestinal parasite infections, as being an anthelmintic drug. Recently, several papers suggest the niclosamide inhibits multiple signaling pathways, which are highly activated and mutated in cancer. Here, niclosamide was evaluated for identifying strategies to overcome tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) resistance. Although niclosamide (100⁻200 nM) alone did not bring about cell death, combinations of niclosamide and TRAIL led to apoptotic cell death in carcinoma cells, but not in normal cells. Niclosamide markedly increased DR5 protein levels, including cell-surface DR5, and decreased c-FLIP protein levels. Down-regulation of DR5 by specific small interfering RNA (siRNA) and ectopic expression of c-FLIP markedly blocked niclosamide plus TRAIL-induced apoptosis. Our findings provide that niclosamide could overcome resistance to TRAIL through up-regulating DR5 on the cell surface and down-regulating c-FLIP in cancer cells. Taken together, niclosamide may be an attractive candidate to overcome TRAIL resistance.

Download full-text PDF

Source
http://dx.doi.org/10.3390/molecules23092264DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225471PMC
September 2018

Publication Analysis

Top Keywords

cells niclosamide
12
niclosamide
9
cell death
8
trail resistance
8
protein levels
8
dr5
5
trail
5
markedly increased
4
increased dr5
4
niclosamide markedly
4
normal cells
4
cells normal
4
c-flip protein
4
including cell-surface
4
carcinoma cells
4
levels including
4
dr5 protein
4
decreased c-flip
4
cell-surface dr5
4
dr5 decreased
4

Similar Publications